Patients Treated With ABL vs Patients Treated With TPTD: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.000907 | 0.000493 | 0.00167 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.000816 | 0.000429 | 0.00155 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.0000907 | -0.000752 | 0.000945 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.11 | 0.452 | 2.73 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.11 | 0.451 | 2.74 | log | ClinicalTrials.gov | |
| Number needed to harm, for one more death from any cause on Patients Treated With ABL than on Patients Treated With TPTD | 11,000 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Patients Treated With ABL | Patients who filled ≥ 1 prescription for ABL (TYMLOS) as their index medication during the identification period. | 10 | 11,027 | EG000 | ClinicalTrials.gov |
| Group 2 | Patients Treated With TPTD | Patients who filled ≥ 1 prescription for TPTD (Forteo) as their index medication during the identification period. | 9 | 11,027 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, all-cause mortality | ClinicalTrials.gov |
| Time frame | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women | ClinicalTrials.gov |
| NCT number | NCT04974723 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Osteoporosis, Postmenopausal | ClinicalTrials.gov |
| Interventions | Abaloparatide, Teriparatide | ClinicalTrials.gov |
| Lead sponsor | Radius Health, Inc. | ClinicalTrials.gov |
| Results first posted | 2024-04-19 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT04974723?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.